Form 4: Director Gina Chapman Receives Stock Options at Entrada

Entrada Therapeutics director Gina Chapman was granted 19,000 stock options as part of standard equity compensation.

Summary

• Director Gina Chapman was granted 19,000 stock options to purchase common stock in Entrada Therapeutics, Inc.
• The options have an exercise price of $5.97 per share.
• The grant date for these options is June 10, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries neutral sentiment for the stock price.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $5.97 exercise price.

Future Outlook

The options vest on the earlier of the one-year anniversary of the grant date or the issuer's next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of time-based vesting for director options is consistent with standard practices for mid-cap biotechnology firms.
• The grant size is typical for independent director compensation packages in the life sciences industry.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options on the earlier of June 10, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Form 4, Insider Trading, Stock Options, Director Compensation